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Abstract
Blacks in comparison to whites are at risk for a more serious form of hypertension with high rates
of complications. Greater sodium retention is thought to underlie the blood pressure (BP)-
determining physiology of blacks, but specific mechanisms have not been identified. In a
prospective observational study of BP, 226 black children and 314 white children (mean age 10.6)
were enrolled initially. Assessments were repeated in 85 blacks and 136 whites after reaching
adulthood (mean age 31). The relationship of BP to the plasma aldosterone concentration (PAC) in
the context of the prevailing level of plasma renin activity (PRA) was studied in blacks and
whites. In a secondary interventional study, 9-α fludrocortisone was administered for 2 weeks to
healthy adult blacks and whites to simulate hyperaldosteronism. BP responses in the two race
groups were then compared. Although PRA and PAC were lower in black children, BP was
positively associated with PAC, an effect that increased as PRA decreased (p=0.004). Data from
black adults yielded similar results. No similar relationship was observed in whites. In the
interventional study, 9-α fludrocortisone increased BP in blacks but not in whites. In conclusion,
aldosterone sensitivity is a significant determinant of BP in young blacks. Although its role in
establishing risk of hypertension is not known, it could be as relevant as the actual level of
aldosterone.
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INTRODUCTION
Blacks in comparisons to whites have disproportionately more hypertension1 and suffer
hypertensive complications at higher rates 2, 3. The etiology of hypertension appears to
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center on overly efficient sodium reabsorption by the kidney. The renin-angiotensin system,
for example, is more likely to be suppressed in blacks than in whites consistent with greater
volume expansion from sodium accumulation and water retention4, 5. In addition, the blood
pressure (BP) in blacks in contrast to the BP in whites is more likely to increase in response
to sodium intake (there is greater ‘salt sensitivity’)6, 7. Whether blacks have a unique renal
physiology that puts them at risk for a more aggressive form of hypertension is unclear. A
more complete understanding of how BP is regulated in blacks could revise current
approaches for treatment should hypertension develop.
A higher production rate of aldosterone, the principal sodium-retaining hormone, is
becoming increasingly appreciated as a contributor to the pathophysiology of hypertension.
Primary hyperaldosteronism, for example, accounts for ~10% of cases of essential
hypertension 8 and ~20% of cases of resistant hypertension 9. In the Framingham Offspring
Study, normotensive individuals with levels of plasma aldosterone in the upper quartile of
the normal range compared to those in the lower quartile when studied four years later had
significantly higher BPs and were more likely to be hypertensive10. In blacks, BP has been
shown in several studies to be positively related to the level of plasma aldosterone11-15. In
some instances, BP 14, 15, presence or absence of hypertension11-13 and/or left ventricular
mass 12, 15 were positively associated with the aldosterone-renin ratio. Despite evidence that
aldosterone has the potential to affect BP, blacks often achieve a higher BP without a
proportionate increase in the aldosterone level.
More than twenty years ago, we initiated a cohort study of BP regulation where enrollees
were children, blacks and whites, from Indianapolis, IN 16. We found that the black children
had lower plasma aldosterone levels and urinary aldosterone excretion rates than the white
children; there was little if any race difference in BP. Other investigative groups have also
found lower aldosterone production in blacks 15, 17, 18. The presumptive explanation was a
suppressed renin-angiotensin axis from greater sodium retention in blacks. On a background
of more positive sodium balance and lower aldosterone production rates, the role of
aldosterone in determining BP could be diminished in blacks. Alternatively, pre-existing
sodium retention might enhance an effect of aldosterone on BP – just as blacks are more
salt-sensitive, they may also be more sensitive to aldosterone.
The present study sought to determine the extent of aldosterone's influence on BP in blacks
in comparison to whites. We undertook a new assessment of the Indianapolis cohort data
collected in childhood as well as an assessment of data collected recently with subjects now
adults. On novel analyses, BP in blacks was found to increase as the plasma aldosterone
concentration (PAC) increased and the level of plasma renin activity (PRA) decreased, a
relationship that was largely absent in whites. The results from observational data led us to
perform a second study, an intervention where blacks and whites were treated with the
synthetic mineralocorticoid 9-α fludrocortisone to simulate modest hyperaldosteronism. The
BP responses in the two race groups were then compared.
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METHODS
Observational Cohort Study
Subjects and Study Design—Data for the main analysis were collected from a
prospective observational cohort study that was started in 1986. The characteristics of the
study participants and the data collection process were described in detail previously.16, 19
Briefly, however, healthy black children and white children between 5 and 17 years of age
were recruited from schools in Indianapolis selected to provide a range of socioeconomic
levels. Renal or cardiac disease, hypertension, diabetes mellitus, and use of medications that
could affect BP excluded subjects from participation. Subjects were seen twice a year. BP
was measured in the right arm while in the seated position after resting for approximately
five minutes. Three BP readings were taken two minutes apart. The average of the last two
readings was used as the final BP measurement. Height and weight were also measured.
Blood samples were drawn in most subjects only once and between 0800 and 1000 hr after
sitting for 15 min. Urine samples were collected overnight.
In 2008, we invited those who had participated as children to return for further evaluations
as adults. The data collection protocol and procedures followed for the adults remained
unchanged from the child study with the exception that blood sampling was carried out at
each visit. To eliminate the possible influences of antihypertensive medication on BP and
biochemical measurements, the current analysis excluded 32 visits from 14 individuals (7
blacks and 7 whites) who were receiving antihypertensive medications. The study protocol
was approved by the Institutional Review Board of Indiana University. Consent was
obtained from all adult participants and from parents of children under 18; assent was
obtained from children as appropriate.
Fludrocortisone Interventional Study
In a secondary study, we tested the hypothesis that administration of a synthetic
mineralocorticoid similar to aldosterone, 9-α fludrocortisone, would raise BP more in blacks
than in whites. In addition, parameters reflective of the state of sodium balance including
level of PRA, PAC and B-type natriuretic peptide (BNP)20 were measured at baseline and
after two weeks of treatment. Healthy subjects were recruited from local medical center
facilities. The study was approved by the Indiana University and the Department of Veterans
Affairs Institutional Review Board. Each subject gave informed consent.
Measurements made at baseline and after two weeks of treatment with 9-α fludrocortisone
were used in the analysis. Subjects were also seen at one week as part of an overall
assessment. Ambulatory BP monitoring (ABPM) was carried out at baseline and after the
two weeks of treatment (Spacelab 90207, Redmond, WA). BP was automatically measured
every 30 minutes during the day and every 60 minutes overnight (2200 to 0800 hr) for 24 hr.
After the first set of measurements, subjects were given 9-α fludrocortisone (0.2 mg as
tablets each morning, which was approximately twice the replacement dose of aldosterone)
for two weeks. Compliance was determined from pill counts at 1 and 2 weeks; no difference
between groups was observed.
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Assay Procedures (see online Supplement)
Statistical Analysis—Demographic and clinical characteristics of the study participants
were summarized by selfreported black and white categories. Continuous variables were
compared by t test and categorical variables by chi-squared tests. To assess the accuracy of
the self-identified race information, we performed a principle component analysis 21.
Specifically, we compared the self-reported race identified in the collected samples to seven
ethnic groups in HAPMAP phase 3 data. Analysis (shown in Supplemental Figure S1)
revealed close genetic resemblance between self-identified blacks in our cohort and
individuals of African ancestry in Southwest United States, and between self-identified
whites and Utah residents of Northern and Western European ancestry.
For the childhood data, we converted all BP values into age, sex, and height adjusted
percentile values.22 We then used varying-coefficient regression models to examine the
influences of aldosterone on BP percentile at different renin levels. Unlike traditional linear
regression analysis, varying-coefficient regression characterizes the effect of aldosterone on
BP as a smooth function of renin.23 In this analysis, regression analysis was performed using
systolic BP percentile as the response variable and the regression coefficient of aldosterone
was modeled as a function of renin. Separate analyses were performed for blacks and
whites. Estimated aldosterone effects on BP were displayed graphically with corresponding
95% confidence intervals. We analyzed the adult data similarly using systolic BP values
instead of percentiles as the response variable. The same analytical approach was used to
examine the effects of urinary aldosterone excretion rate (per mg. of urinary creatinine) on
systolic BP percentile in children and systolic BP in adults at different levels of PRA.
In the interventional study, we determined changes in clinic BP, ABPM (day time, night
time and 24 hours) and body weight, as well as changes in plasma levels of BNP, renin
activity and aldosterone. The responses of the aldosterone-renin ratio were also calculated
over the two weeks. The magnitudes of the within-subject changes were examined using a
paired t-test; changes between the race groups were compared using analysis of variance
adjusted for the effects of age, BMI, and sex. The analysis was implemented by using in R
software (R Core Team (2013). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/).
Throughout the analysis, p values less than 0.05 were considered statistically significant.
RESULTS
Subjects
Characteristics of the children at the initial enrollment and of the adults when re-enrolled are
presented in Table 1. Characteristics of the subjects in the interventional study are also
presented. The levels of PRA and the PAC in children (obtained at a visit that was
subsequent to the enrollment visit) and in adults were significantly lower in blacks
regardless of the age group (Figure 1); in black children, the PAC/PRA ratio was
significantly lower. Mean values for plasma measurements and for urinary aldosterone and
electrolyte excretion rates are available in Supplemental Table S1.
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Aldosterone sensitivity
Using varying-coefficient regression analysis, we estimated the effect of PAC on systolic BP
in blacks and whites in children as well as in adults. The effects of aldosterone on systolic
BP percentiles are depicted in Figure 2 as smooth functions of PRA. The plots showed two
distinctly dissimilar patterns of influences of PAC on systolic BP at the various levels of
PRA in the two race groups. In whites, the estimated PAC-BP association consisted of a
barely discernable increase as PRA increased, the confidence interval overlapped with the
zero effect and thus this was not statistically significant. In blacks, the estimated BP effect of
aldosterone was highly significant (p=0.004) and became stronger as the level of PRA
declined. For example, in children with PRA of 1.0 ng/ml/h, there was on average a 2%
increase in the systolic BP percentile for each ng/dl increase in PAC. Importantly, the PAC
effect on systolic BP in the adults showed similar patterns: the BP responded strongly to
aldosterone in the blacks, especially in those with lower PRA. A similar pattern was once
again not evident in the whites. The relation of urinary aldosterone excretion to BP at
different PRA levels was also examined. Analysis showed a similar race difference (see
Supplemental Figure S2).
9-α Fludrocortisone
The BP responses to 9-α fludrocortisone administered over 2 weeks were clearly different in
blacks and whites (Figure 3). Whereas in whites BP did not change, in blacks systolic BP
increased by 5-6 mmHg (p=0.034 for clinic BP, p<0.001 for daytime ABPM, p=0.006 for
nighttime ABPM, and p=0.001 for ABPM over 24 hours). Weight increased in blacks
(p=0.028) and not in whites (p=0.11). Similarly, levels of BNT increased only in blacks
(p=0.012). PRA decreased in blacks (p=0.002) and in whites (p<0.001). Although PAC
decreased significantly in both race groups (p=0.010 for blacks and p<0.001 for whites) the
magnitude of the decrease was significantly greater for whites (p=0.014). The aldosterone-
renin ratio increased in response to 9-α fludrocortisone in whites (p=0.036) and showed a
marginally significant decrease in blacks (p=0.09). In blacks only, the serum potassium
concentration decreased by 0.2 mmol/L with treatment (p=0.0008).
DISCUSSION
In the current study, we assessed the role of aldosterone in regulating BP in young blacks
and whites. We employed an analytical approach that took into account the prevailing state
of sodium retention as reflected in the level of PRA. In the blacks, BP showed a significant
association with PAC. This effect of aldosterone on BP or aldosterone sensitivity intensified
as PRA decreased. The findings were evident in both children and adults. A similar effect
pattern was not observed in whites. In a separate study, the 24 hour ambulatory BP response
of young blacks and whites to administrated 9-α fludrocortisone were determined, an
intervention that in effect directly tested for aldosterone sensitivity. BP increased
significantly in the blacks but not in the whites. The results corroborated the finding in the
association study. Sensitivity of BP to the circulating level of aldosterone may be an integral
component of the BP-determining physiology in young blacks.
Tu et al. Page 5
Hypertension. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
A mechanism for why young blacks have a heightened sensitivity to aldosterone may reside
with a pre-existing state of increased sodium retention. This was implied by the lower level
of PRA that inversely correlated with aldosterone's positive influence on BP, pointing to an
expansion of fluid volume. In blacks, less additional sodium uptake by aldosterone would be
required to reach a threshold where BP might increase. The response by blacks to treatment
with 9-α fludrocortisone was also consistent with having greater baseline sodium stores. In
contrast to whites, blacks experienced significant weight gain and an increase in their level
of BNP, a marker of volume and which would be expected to increase as extracellular fluid
volume expanded20. It was as if the capacity for taking on any additional sodium had
already been fully realized in the blacks and achieving sodium balance would rely more on a
natriuresis from an increase in BP 24, 25 . The whites on the other hand seemed to adjust to
additional sodium or an increase in volume without resorting to an increase in BP. Indeed,
the whites showed a significant decrease in levels of PRA and PAC whereas the blacks did
not, suggesting that whites have a greater capacity for accommodating additional sodium.
Urinary excretion rates of sodium and potassium were not measured in the interventional
study. Although a potential shortcoming, race differences in what was consumed would
likely have affected findings at baseline more than response to 9-α fludrocortisone and it
was these results that were most noteworthy.
Aldosterone sensitivity was delineated in the blacks using analyses that simultaneously took
into account the dual influences of plasma aldosterone and PRA on BP. If we had relied only
on the aldosterone-renin ratio, which is used commonly as a clinical tool to assist in
diagnosing primary hyperaldosteronism 8, it could have led to our having missed
recognizing aldosterone sensitivity in the blacks. Various combinations of the levels of
aldosterone and renin activity can give identical values for the aldosterone-renin ratio while
at the same time quite different propensities for affecting BP. The black children in our
study, for example, had significantly lower aldosterone-renin ratios than the white children
yet ultimately we found that aldosterone was a principal determinant of the BP.
The present study was not intended to lend itself to suggesting a better treatment for
hypertensive blacks. However, in an earlier randomized, placebo-controlled study limited to
blacks with poorly controlled low-renin hypertension, adding in small doses of
spironolactone (a mineralocorticoid receptor antagonist) and/or amiloride (an inhibitor of the
epithelial sodium channel, a principal target of aldosterone) lowered the average BP into the
normal range 26. In a comparison between race groups of the antihypertensive properties of
the mineralocorticoid receptor antagonist, eplerenone, blacks and whites were found to
respond equally 27. In the same study, however, the blacks showed a significantly better BP-
lowering response to eplerenone than to the angiotensin receptor blocker, losartan, whereas
in the whites eplerenone as an antihypertensive was not superior to losartan.
The propensity to retain sodium and develop hypertension is very much age-dependent 7. As
people become older, aldosterone sensitivity may also become more common and may occur
regardless of race but earlier and probably more often in blacks. Non-pressor effects of
aldosterone 28 might also be enhanced when sensitivity to aldosterone is increased. The
present findings also raise the question of what constitutes a normal aldosterone level in
blacks and at what level is it too high, especially for the level of PRA and thus amendable to
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a treatment that mitigates aldosterone's actions. Answers to these questions could impact
greatly on management of hypertension.
Our findings suggest that the serious nature of the hypertension in blacks is related to
mechanisms specific for this population group. Genetic backgrounds selected for the
survival advantages offered by highly developed renal sodium conservation mechanisms
were likely contributors. We did not study hypertension per se but instead the normal
physiology, although in so doing, we avoided the confounders that can accompany inclusion
of hypertensives such as effects of antihypertensive medications.
PERSPECTIVE
Until now, aldosterone production has been the focus of studies for how aldosterone
influences BP. We can now add aldosterone sensitivity to the equation for a more complete
picture of aldosterone's sodium-retaining properties that affect risk for hypertension. The
mechanisms that confer aldosterone sensitivity, which would seem to include increases in
sodium retention, will be challenging to delineate. Treatment approaches that antagonize
aldosterone's actions or target mechanisms that instill sensitivity to aldosterone could have
enormous relevance to the prevention of stroke, end stage renal disease and heart disease in
blacks.
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Novelty and Significance
What Is New?
• Sensitivity of blood pressure to aldosterone is described for the first time.
• It was present in black children and in black young adults but not in whites of
comparable age.
• Although blacks may have on average lower plasma aldosterone levels than
whites, the level of aldosterone may nonetheless still impact on BP because of
aldosterone sensitivity.
What Is Relevant?
• Although we did not study hypertension per se, the findings strongly imply a
fundamental role of aldosterone in the development of hypertension in many
blacks. A normal plasma aldosterone level in a black patient with hypertension
may not rule out participation by aldosterone in the pathophysiology.
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Figure 1.
The mean levels of plasma renin activity (PRA), plasma aldosterone concentration (PAC),
and the aldosterone-renin ratio (ARR) with corresponding 95% confidence intervals in
blacks and in whites, in children and in adults.
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Figure 2.
Estimated aldosterone effects on systolic BP (SBP) and systolic BP percentiles (SBP%) in
blacks and in whites. For children, the effect is expressed as the average increase in SBP%
associated with 1 ng/dL increase in PAC. For adults, the effect is expressed as the average
increase in SBP associated with 1 ng/dL increase in PAC at a given level of PRA. (a)
Estimated effect of PAC on SBP% at different levels of PRA in white children, (b) in black
children, (c) estimated effect of PAC on SBP as a function of PRA in white adults and (d) in
black adults. The analyses were adjusted for age, sex, and BMI.
In black children, PAC was significantly associated with SBP%, especially when PRA was
low. In white children, no significant association was detected (Panels (a) and (b)). Similar
associations were found in adults [Panels (c) and (d)].
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Figure 3.
Changes from baseline in response to two weeks of treatment with 9-α fludrocortisone for
systolic BP measured manually (‘clinic’) and with ambulatory BP monitoring (ABPM),
weight, level of B-type natriuretic peptide (BNP), level of PRA, PAC, and PAC/PRA
(values depicted with corresponding 95% confidence intervals).
Systolic BP increased in blacks measured in clinic (p=0.034) and with ABPM (p<0.001
during daytime, p=0.006 overnight, and p<0.001 over 24 hr). In blacks, there were
significant increases in weight (p=0.028) and BNP (p=0.012). PRA decreased significantly
in blacks (p =0.002) and whites (p<0.001); PAC decreased in blacks (p=0.010) and whites
(p<0.001). PAC/PRA increased in whites (p=0.036) and decreased marginally in blacks
(p=0.09).
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Table 1
Characteristics of subjects.
Variable Full sample Black White P value
Characteristics of the children at time of enrollment.
N 540 226 314
Male, n (%) 273 (51%) 105 (46%) 168 (54%) 0.107
Age (yrs) (range: 5 -17) 10.6 (3.0) 11.5 (2.9) 10.0 (2.9) <0.001
Systolic BP (mm Hg) 101 (12) 103 (11) 100 (12) <0.001
Systolic BP% 42 (26) 43 (27) 41 (26) 0.448
Diastolic BP (mm Hg) 62 (10) 63 (10) 61 (11) 0.027
Diastolic BP% 52 (26) 52 (25) 51 (26) 0.712
BMI% 63 (28) 70 (28) 58 (28) <0.001
Characteristics of the adults at time of re-enrollment.
N 221 85 136
Male, n (%) 106 (48%) 39 (46%) 67 (49%) 0.626
Age (yr) (range 20 -39) 30.8 (4.2) 29.4 (4.0) 31.6 (4.1) <0.001
Systolic BP (mm Hg) 116 (11) 116 (11) 116 (11) 0.713
Diastolic BP (mm Hg) 74 (10) 74 (11) 74 (10) 0.975
BMI (kg/m2) 29 (8) 31 (8) 28 (8) 0.002
Characteristics of subjects in the intervention study.
N 38 20 18
Male, n (%) 15 (39%) 9 (45%) 6 (33%) 0.463
Age (yr) (range 19 -36) 27.0 (4.9) 27.9 (4.8) 26.1 (5.0) 0.455
Systolic BP (mm Hg) 112 (10) 110 (8) 115 (12) 0.022
Diastolic BP (mm Hg) 68 (8) 68 (8) 69 (8) 0.524
BMI (kg/m2) 27 (6) 28 (5) 25 (6) 0.167
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